Beyang Therapeutics, a Shanghai, China-based AI-driven drug discovery company, raised nearly $30M in Series A funding.
The round was co-led by Legend Capital and Shanghai Healthcare Capital, with participation from China Medical System Holdings Limited, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, Harbor & Canton Capital, Root Venture Partners, and YuanBio Venture Capital.
The company intends to use the funds to accelerate the technological iteration of its proprietary AI + Molecular Design and Optimization platform (ExCEED), advance key pipeline candidates through clinical and pre-clinical development, and expand its international R&D and business development teams.
Led by Founder Qiyue Hu, Beyang Therapeutics is an AI-driven innovative drug R&D company developing a platform, ExCEED, that integrates proprietary databases with AI and computational simulation technologies across molecular design, druggability optimization, and biological evaluation to generate new scaffolds and optimize candidates.
They currently maintain a pipeline including BT01001, a non-invasive eye drop candidate for fundus oculi diseases advancing toward First-in-Patient trials, and BT01002, a second-generation Menin inhibitor undergoing IND-enabling studies.
Don’t just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week—in our structured Master Database (XML) + Weekly Intelligence PDF. 👉 [Access FinSMEs Intelligence Hub]
FinSMEs
12/08/2026